Immune System Diseases

926 trials 377 recruiting

Filter these 926 trials by phase, country and sponsor.

Open in Search →

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-C3 in Adult Healthy V… Ended

2023-506690-36-00 complement-mediated renal disease 9 2024-05-06
MK-2420 SAD Study Ended

2024-511297-73-00 Rheumatoid arthritis 1 2024-05-03
A Study of the Efficacy, Safety, and Tolerability of KAN-101 in Participants With Celiac Disease Ended

2023-507240-37-00 celiac disease 4 2024-04-30
Rapid pain control in Ixekizumab targeted axial spondyloarthritis Ended

2023-508976-12-00 axial spondyloarthritis 6 2024-04-29
A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin Ended

2023-509339-17-00 Inflammatory bowel disease 3 2024-04-15
Proof-of-concept study evaluating subcutaneous amlitelimab in adult participants with moderate to severe hidradenitis suppurativa. Ended

2023-505803-22-00 Hidradenitis 4 2024-04-15
A placebo-controlled safety and tolerability study of intravenous (IV) and subcutaneous (SC) AZD1163 in healthy volunteers Ended

2023-509574-34-00 Rheumatoid Arthritis 1 2024-04-10
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to… Ended

2023-504564-42-00 Moderate to Severe Rheumatoid Arthritis 4 2024-04-08
A phase IIb study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis Ended

2023-506477-35-00 moderate to severe plaque psoriasis 4 2024-04-02
Investigating the safety, feasibility, and optimal dose of Adalimumab-680LT in IBD – GUIDE study Ended

2023-508391-11-00 Inflammatory Bowel Disease (IBD) 7 2024-03-21
A study to assess the effect of single and repeated doses of JNJ-81241459 on a single dose of certain other drugs, when given together to he… Ended

2023-509030-19-00 Plaque Psoriasis 3 2024-03-18
A clinical study of MK-6194 for the treatment of Systemic Lupus Erythematosus (SLE) (MK-6194-006) Ended

2023-505520-61-00 Systemic Lupus Erythematosus 10 2024-03-11
A six-way relative bioavailability study comparing 10, 30, 40 and 50 mg leniolisib film coated tablets and 30 mg film coated granules with 7… Ended

2023-508880-61-00 Activated Phosphoinositide 3-Kinase Delta Syndrome 3 2024-03-06
A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Pa… Ended

2023-507534-24-00 Chronic Inducible Urticaria 9 2024-03-06
Transfer of metformin into human breast milk and the plasma of breastfeeding children - A low intervention trial with biobanking of breast m… Ended

2022-501693-19-00 type 2 diabetes mellitus and gestational diabetes melli 6 2024-03-06
Transfer of prednisolone into human breast milk and plasma of breastfeeding children Ended

2023-508913-18-00 Reumatoid Arthritis, SLE, myositis, psoriatric arthriti 6 2024-03-05
A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended

2023-503910-60-00 Rheumatoid arthritis 4 2024-03-05
A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe Asthma Ended

2023-504304-29-00 Moderate to Severe Asthma 3 2024-03-01
A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by t… Ended

2023-508030-33-00 Healthy volunteers 8 2024-03-01
A Phase 1b Study of Imvotamab in Severe Systemic Lupus Erythematosus Ended

2023-506499-29-00 Systemic Lupus Erythematosus 3 2024-02-28
A prospective, randomized, double-blind placebo-controlled multicentre study with mannan-conjugated birch pollen allergoids administered sub… Ended

2023-508013-16-00 Birch pollen induced allergic rhinitis or rhinoconjunct 5 2024-02-26
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple doses Ended

2023-507882-24-00 Inflammatory Gastrointestinal Disease 1 2024-02-20
A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended

2022-502461-23-00 Prurigo Nodularis 5 2024-02-15
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis Ended

2023-505127-31-00 Rheumatoid Arthritis 3 2024-02-08